TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Clade Therapeutics Completes Acquisition of Gadeta B.V

Tuesday, October 03, 2023

Clade Therapeutics, a biopharmaceutical company specializing in the development of engineerable, scalable stem cell-based medicines, has announced the successful completion of its acquisition of Gadeta B.V. Gadeta B.V. is a cell therapy company that focuses on pioneering innovative gamma/delta (g/d) T-cell receptor (TCR)-based immunotherapies for cancer patients.

Gadeta is an international research and development company dedicated to advancing cancer immunotherapies. The company has developed a proprietary platform for engineering novel g/d TCRs with broad tumor-targeting capabilities. These specialized g/d TCRs can identify specific patterns or markers on the surface of cancer cells, distinguishing them as diseased and effectively targeting cancer cells while sparing healthy ones.

This acquisition represents a significant development for Clade, providing access to preclinical cell therapy programs, a g/d TCR discovery engine, and a range of cell enhancement technologies aimed at improving the effectiveness of cell therapies. The integration of Gadeta's g/d TCR targeting technology is seen as complementary to Clade's existing cellular platform, further advancing the development of engineerable, scalable, and consistent stem cell-based medicines.

Under the terms of the acquisition agreement, Clade has acquired all outstanding shares of Gadeta, making it a wholly owned subsidiary of Clade. Gadeta shareholders will receive upfront and downstream economic benefits.

Chad Cowan, Ph.D., Chief Executive Officer of Clade Therapeutics, expressed, Clade is at the forefront of expanding the impact of cell therapy by establishing a more robust cellular platform with stem-cell-derived immune cells. Our technology platform includes a 'Cell Foundry' for generating adult immune cells, including both CD8+ and CD4+ T Cells, as well as a 'Cloaking Engine' for ensuring top-tier protection from the host's immune system. The acquisition of Gadeta represents a strategic step towards integrating a third element into our platform: 'Universal Targeting.' This seamless integration complements Clade's existing platform and commitment to developing engineerable, scalable, and consistent cell medicines.

Jim Glasheen, Ph.D., President and Chief Business Officer of Clade Therapeutics, added, Gadeta has generated compelling in-vitro and in-vivo data in recent years with its leading gamma/delta (g/d) TCRs for solid tumor indications. We are excited to incorporate this novel targeting into Clade's solid tumor programs. Clade's pipeline focuses on replicating the benefits of autologous cell therapy products while addressing their limitations, such as inconsistent quality, logistical challenges, and scalability. This acquisition reinforces our belief that Clade's engineerable platform provides the ideal foundation for integrating compelling innovations emerging from the autologous cell therapy ecosystem.

Marcel Zwaal, Chief Executive Officer of Gadeta, expressed, Today marks a significant milestone in Gadeta's journey. Our pipeline of novel, distinctive g/d TCRs holds the potential to significantly impact the lives of patients with solid tumors. This strategic transaction with Clade Therapeutics represents a major step toward bringing our novel g/d TCRs to the clinic in an off-the-shelf platform.

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit